XML 53 R32.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Acquisitions, Research Collaborations and License Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract] |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The estimated fair value of assets acquired and liabilities assumed from Acceleron is as follows:
|  | November 19, 2021
Cash and cash equivalents |  | $ | 340 |
Investments |  | 285 |
Identifiable intangible assets: (1) |  |
IPR&D - sotatercept |  | 6,380 |
Products and product rights - Reblozyl (12 year useful life) |  | 3,830 |
Deferred income tax liabilities, net |  | (1,832) |
Other assets and liabilities, net |  | 89 |
Total identifiable net assets |  | 9,092 |
Goodwill (2) |  | 2,422 |
Consideration transferred |  | $ | 11,514 |
(1) The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed. (2) The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes. The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
| January 16, 2020
Cash and cash equivalents | $ | 145 |
IPR&D - nemtabrutinib (1) | 2,280 |
Licensing arrangement for ARQ 087 | 80 |
Deferred income tax liabilities | (361) |
Other assets and liabilities, net | 34 |
Total identifiable net assets | 2,178 |
Goodwill (2) | 512 |
Consideration transferred | $ | 2,690 |
(1) The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. (2) The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:
| April 1, 2019
Cash and cash equivalents | $ | 31 |
Accounts receivable | 73 |
Inventories | 93 |
Property, plant and equipment | 60 |
Identifiable intangible assets (useful lives ranging from 18-24 years) (1) | 2,689 |
Deferred income tax liabilities | (589) |
Other assets and liabilities, net | (82) |
Total identifiable net assets | 2,275 |
Goodwill (2) | 1,376 |
Consideration transferred | $ | 3,651 |
(1) The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. (2) The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationAndAssetAcquisitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration